Oncopeptides AB (publ) (ONCO) Q2 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Oncopeptides Ab.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.476 Welcome to Oncopeptide's second quarter earnings call for 2026. 00:00:04.476 -- 00:00:09.181 For the first part of the conference call, the participants will be in listen-only mode. 00:00:09.181 -- 00:00:13.865 During the questions and answers session, participants are able to ask questions by dialing 00:00:13.865 -- 00:00:19.091 pound key 5 on their telephone keypad. Now I will hand the conference over to CEO 00:00:19.091 -- 00:00:24.615 Sophia Haggis and CFO Henrik Bergentoft. Please go ahead. 00:00:24.954 -- 00:00:31.598 Welcome to the Oncopeptides webcast for the second quarter of 2026. 00:00:32.360 -- 00:00:37.064 Please note the disclaimer regarding forward-looking statements. 00:00:37.064 -- 00:00:43.468 Today's presentation is led by me, Sofia Heggis, and our CFO, Henrik Bergentoft. 00:00:43.730 -- 00:00:48.392 We delivered net sales of 31.1 million SEK in Q2 2026, 00:00:50.243 -- 00:00:56.387 representing a 62% increase compared to Q2 2025. 00:00:56.387 -- 00:01:00.410 For the first half of the year, net sales reached 00:01:00.410 -- 00:01:06.814 56.5 million SEK, up with 74% year over year. 00:01:06.814 -- 00:01:11.938 Following the rights issue completed earlier this year, our cash position stood 00:01:11.938 -- 00:01:16.579 at 158 million SEK at the end of the second quarter. 00:01:16.579 -- 00:01:22.660 we remain on track towards reaching positive cash flow during 2027. 00:01:24.022 -- 00:01:29.024 During the second quarter, we achieved several critical commercial, clinical 00:01:29.024 -- 00:01:34.165 and regulatory milestones, which demonstrates that even though our organization 00:01:34.165 -- 00:01:39.507 is lean, oncopeptides consists of people with high level of competence, 00:01:39.507 -- 00:01:42.550 motivation...